<SEC-DOCUMENT>0001558370-19-000070.txt : 20190107
<SEC-HEADER>0001558370-19-000070.hdr.sgml : 20190107
<ACCEPTANCE-DATETIME>20190107091537
ACCESSION NUMBER:		0001558370-19-000070
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190103
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190107
DATE AS OF CHANGE:		20190107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AxoGen, Inc.
		CENTRAL INDEX KEY:			0000805928
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				411301878
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36046
		FILM NUMBER:		19512381

	BUSINESS ADDRESS:	
		STREET 1:		13631 PROGRESS BLVD.
		STREET 2:		SUITE 400
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615
		BUSINESS PHONE:		(386) 462-6817

	MAIL ADDRESS:	
		STREET 1:		13631 PROGRESS BLVD.
		STREET 2:		SUITE 400
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LECTEC CORP /MN/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8-k.htm
<DESCRIPTION>8-K
<TEXT>
<!--HTML document created with Merrill Bridge  8.3.0.54-->
<!--Created on: 1/7/2019 7:15:24 AM-->
<html>
	<head>
		<title>
			axgn_20190103_PRE-ER_8K
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;border-top:3pt solid #000000 ;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt solid #000000 ;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">UNITED STATES</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">Washington, D.C. 20549</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 16pt;">
			<font style="display:inline;font-size:16pt;">Form 8-K</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-weight:bold;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Current Report</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of&nbsp;1934</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">Date of Report (Date of earliest event reported): January 3, 2019</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 16pt;">
			<font style="display:inline;font-size:16pt;">AXOGEN, INC</font><font style="display:inline;">.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Exact name of registrant as specified in its charter)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:31.38%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">Minnesota</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.10%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:35.60%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">001-36046</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.10%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:28.84%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">41-1301878</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:31.38%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(State or other jurisdiction of</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.10%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:35.60%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(Commission&nbsp;File&nbsp;Number)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.10%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:28.84%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(IRS Employer Identification&nbsp;No.)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:31.38%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">incorporation)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.10%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:35.60%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.10%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:28.84%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:50.22%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">13631 Progress Boulevard, Suite 400,</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.14%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:47.64%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.22%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">Alachua,&nbsp;Florida </font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.14%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.64%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">32615</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.22%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(Address of Principal&nbsp;Executive&nbsp;Offices)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.14%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:47.64%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(Zip Code)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Registrant&#x2019;s telephone number, including area code</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:100.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">(386) 462-6800</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:100.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(Former name or former address if changed since last report,)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;Written&nbsp;communications&nbsp;pursuant&nbsp;to&nbsp;Rule&nbsp;425&nbsp;under&nbsp;the&nbsp;Securities&nbsp;Act&nbsp;(17&nbsp;CFR&nbsp;230.425)</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;Soliciting&nbsp;material&nbsp;pursuant&nbsp;to&nbsp;Rule&nbsp;14a-12&nbsp;under&nbsp;the&nbsp;Exchange&nbsp;Act&nbsp;(17&nbsp;CFR&nbsp;240.14a-12)</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#xA7;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#xA7;240.12b-2 of this chapter).</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Emerging growth company </font><font style="display:inline;color:#000000;font-size:9pt;">&#x2610;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="display:inline;color:#000000;font-size:9pt;">&#x2610;</font>
		</p>
		<p style="margin:0.05pt 0pt 0pt;border-bottom:1pt solid #000000 ;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:3pt solid #000000 ;font-family:Calibri;font-size: 1pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0.2pt 0pt 0pt;font-family:Calibri;font-size: 5pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:5.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 11pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Calibri;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">Item 2.02 Results of Operations and Financial Condition</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">On January 7, 2019, AxoGen, Inc. (the &#x201C;Company&#x201D;) issued a press release announcing its estimated fourth quarter and full year 2018 revenue. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1 hereto, shall not be considered &#x201C;filed&#x201D; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201C;Exchange Act&#x201D;), or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered &#x201C;filed&#x201D; or incorporated by reference&nbsp;therein.</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:9pt;">Item 5.02&nbsp; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.&nbsp; </font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:9pt;">As of January 3, 2019, Shawn McCarrey &nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">no longer works at the Company and is pursuing other opportunities.</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">Item 9.01. Financial Statements and Exhibits</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">P</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:83.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:15.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Exhibit&nbsp;No.</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:83.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:15.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">99.1</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:83.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 11pt;">
						<font style="display:inline;"><a href="ex-99d1.htm"><font style="font-family:Times New Roman,Times,serif;font-size:9pt;">AxoGen, Inc. Press Release, dated January 7, 2019.</font></a></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;"></font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 7pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:7pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Calibri;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">EXHIBIT INDEX</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:83.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:15.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Exhibit&nbsp;No.</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:83.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:15.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">99.1</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:83.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 11pt;">
						<font style="display:inline;"><a href="ex-99d1.htm"><font style="font-family:Times New Roman,Times,serif;font-size:9pt;">AxoGen, Inc. Press Release, dated January 7, 2019.</font></a></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;"></font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Calibri;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">SIGNATURE</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:49.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:47.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.02%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">AXOGEN, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.02%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Date: January&nbsp;7,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">By: </font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.16%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">/s/ Gregory&nbsp;G.&nbsp;Freitag</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.16%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Gregory G.&nbsp;Freitag</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.16%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">General Counsel</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:47.16%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Merrill Bridge  8.3.0.54-->
<!--Created on: 1/7/2019 7:15:23 AM-->
<html>
	<head>
		<title>
			Exhibit 99.1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:left;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;"><img src="ex-99d1g001.jpg" style="width: 2.127388in; height: 0.6775525in" alt="axogen-inc-logo.jpg"></font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:center;border-top:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:center;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 14pt;">
			<font style="font-family:Calibri;font-weight:bold;font-size:14pt;display:inline;font-family:Calibri;">AxoGen, Inc. Pre-Announces Financial and Operational Results</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:center;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-weight:bold;font-size:14pt;display:inline;font-family:Calibri;font-weight:normal;font-style:italic;font-size:11pt;">Q4 Revenue of at least $23.4 million, a 38% YoY increase</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-weight:bold;font-size:14pt;display:inline;font-family:Calibri;font-weight:normal;font-style:italic;font-size:11pt;">FY 2018 Revenue of at least $83.9 million, a 39% YoY increase</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:115%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-weight:bold;font-size:14pt;display:inline;font-family:Calibri;font-weight:normal;font-style:italic;font-size:11pt;">Company reaffirms 2019 financial guidance and provides business update</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-style:italic;">Appoints Chris Crisman to Vice President, U.S. Sales</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-weight:bold;font-size:11pt;display:inline;font-family:Calibri;">ALACHUA, FL &#x2013; January 7, 2019 &#x2013; </font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today provided a business update, including preliminary unaudited fourth quarter and full year 2018 results and selected business highlights for the quarter and year ended December 31, 2018.</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;">Preliminary Fourth Quarter and Year-End Performance Highlights</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:115%;text-align:left;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:115%;text-align:left;border-bottom:1pt none #D9D9D9;punctuation-wrap:word-break;text-justify:inter-ideograph;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;text-align:left;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;margin:0pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">Fourth quarter revenue is expected to be at least $23.4 million, up 38% compared to fourth quarter 2017 revenue of $17.0 million</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:115%;text-align:left;border-top:1pt none #D9D9D9;punctuation-wrap:word-break;text-justify:inter-ideograph;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;margin:0pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">Full year 2018 revenue is expected to be at least $83.9 million, up 39% compared to 2017 revenue of $60.4 million</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Ended the fourth quarter with 85 direct sales representatives, an increase of nine representatives in the quarter and 25 year-over-year, as well as 17 independent sales agencies</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Increased active accounts by 33 in the fourth quarter to 712, up 20% from 591 a year ago</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;margin:0pt;">
			<a name="_Hlk534182917"></a><font style="display:inline;font-family:Calibri;font-size:11pt;">Enrolled 168 of 170 target subjects in the RECON study in support of the Company&#x2019;s BLA application for Avance</font><font style="display:inline;font-family:Calibri;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="display:inline;font-family:Calibri;font-size:11pt;"> Nerve Graft</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;margin:0pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Completed 18 national education programs in 2018 and expect to conduct 25 programs in 2019</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:115%;text-align:left;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">&#x201C;The strong growth we delivered in 2018 reflects the progress we are seeing in our core trauma, oral and maxillofacial and breast reconstruction neurotization markets,&#x201D; said Karen Zaderej, chairman, CEO, and president of AxoGen. &#x201C;In 2018, we invested for growth across the organization by expanding our commercial team and surgeon education programs, building our body of clinical evidence, and adding critical capabilities and leadership across the organization. In 2019, we will continue to take steps to drive sharper and more consistent commercial execution and build our platform of nerve repair.&#x201D;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">The Company has separately announced the appointment of Chris Crisman to Vice President, U.S. Sales, succeeding Shawn McCarrey, effective today. </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;punctuation-wrap:word-break;text-align:justify;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;punctuation-wrap:word-break;text-align:justify;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Updates to 2018 Financial Guidance </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Management updates its 2018 revenue guidance and now expects 2018 revenue will be at least $83.9 million. Management reiterates that its full year 2018 gross margin is expected to remain above 80%. </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Reaffirms 2019 Financial Guidance </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Management reiterates that 2019 annual revenue is expected to grow by at least 35% over 2018 revenue and that its gross margin is expected to remain above 80%.&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">The results disclosed in this press release are preliminary and unaudited. The Company will report full, audited results for the fourth quarter and year ended December 31, 2018 on February 26, 2019.</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;text-decoration:underline;">AxoGen 2018 Overview</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;text-decoration:underline;">Market Opportunity and Revenue Diversification</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;">Updated estimated value of market opportunity in existing applications to $2.7 billion </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">As announced at the Company&#x2019;s Annual Analyst and Investor Day in November 2018, AxoGen believes the total addressable U.S. market (TAM) to be $2.7 billion, a $500 million increase from the Company&#x2019;s previous estimate. The revision was primarily driven by updated assumptions for net procedure values, and increased prevalence of Connector Assisted Repair</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-size:8pt;font-size:4pt;top:-4.4pt;position:relative;line-height:115%">SM</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;"> in trauma cases. The $2.7 billion market estimate includes more than 900,000 procedures, with the majority (approximately 700,000) of those procedures in extremity trauma. The Company&#x2019;s extremity trauma market procedure estimate is derived in part from the 2015 National Hospital Ambulatory Medical Care Survey and uses multiple pieces of published literature to determine an appropriate prevalence assumption of nerve repair from annual injury-related emergency room visits.</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;">Increased number of active accounts, further diversifying revenue base</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">The Company has a clear methodology for calculating its number of active accounts, defined as an account </font><font style="display:inline;font-family:Calibri;font-size:11pt;">which has typically gone through the committee approval process, has at least one surgeon who has converted a portion of his or her treatment algorithms of peripheral nerve repair to the AxoGen portfolio and has ordered AxoGen products at least six times in the last 12 months. </font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">The Company ended the 2018 fiscal year with 712 active accounts, an increase of 121 active accounts over the previous year (20% growth). The top 10% of active accounts represented approximately 35% of revenue in the fourth quarter, which has remained fairly consistent over the past several quarters and we believe demonstrates the continued potential for expansion of our revenue base. Expected full year 2018 revenue of at least $83.9 million reflects this large, diverse customer base, supported by an expanding team of direct sales representatives. </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;punctuation-wrap:word-break;text-align:justify;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;punctuation-wrap:word-break;text-align:justify;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Announced 2019 market development and clinical initiatives in the surgical treatment of chronic neuropathic pain</font><font style="display:inline;font-family:Calibri;font-size:11pt;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">AxoGen believes that the surgical treatment of pain represents a market expansion opportunity as surgeons and patients seek a solution for chronic neuropathic pain. The Company estimates that the total addressable market could be more than $2 billion across many applications for the surgical treatment of pain. AxoGen will focus initially on orthopedic and trauma procedures, which are estimated to be approximately $1 billion of the larger opportunity. AxoGen expects to begin several market development and clinical initiatives in 2019 to support a broader commercial launch.</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;text-decoration:underline;">Barriers to Entry </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<a name="_Hlk534183052"></a><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;">Avance</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;"> Nerve Graft Granted Regenerative Medicine Advance Therapy (&#x201C;RMAT&#x201D;) designation by U.S. Food and Drug Administration (FDA)</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;display:inline;font-size:11pt;">In September 2018 the FDA granted a RMAT designation for Avance</font><font style="font-family:Calibri;display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="font-family:Calibri;display:inline;font-size:11pt;"> Nerve Graft. A regenerative medicine therapy is eligible for the designation if it is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such a disease or condition. The RMAT designation provides access to a streamlined approval process for regenerative medicine technologies and ensures continued informal meetings with the FDA in support of the biologic license application (&#x201C;BLA&#x201D;) for Avance</font><font style="font-family:Calibri;display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="font-family:Calibri;display:inline;font-size:11pt;"> Nerve Graft. &nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;display:inline;font-size:11pt;">The Company believes that any future, competitive peripheral nerve allograft would be required to follow the standard pathway for biologic licensing, which typically entails multiple clinical trials and takes many years. The FDA provided updated guidance in December 2017 which made clear that any processing that alters the biological characteristics of peripheral nerve tissue would be considered more than minimal manipulation, and therefore require a BLA prior to marketing. </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;display:inline;font-size:11pt;">The Company has maintained a collaborative dialogue with the FDA and will continue to work closely with the FDA as it progresses towards its BLA submission. Upon BLA approval, Avance</font><font style="font-family:Calibri;display:inline;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="font-family:Calibri;display:inline;font-size:11pt;"> Nerve Graft will have 12 years of data exclusivity with regard to potential biosimilars. </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Robust intellectual property portfolio</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">AxoGen&#x2019;s world-wide intellectual property (&#x201C;IP&#x201D;) portfolio includes trademarks, trade secrets, and numerous patents and, if issued, patent applications, that provide both offensive and defensive protection. Our Avance</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;"> Nerve Graft is protected by several families of patents directed to the grafts and methods of preparation that extend beyond our commercial process.&nbsp;Some such patented methods expressly claim use of &#x201C;anionic sulfonate detergents&#x201D; or &#x201C;anionic surface-active detergents&#x201D;, only one of which is Triton X-200. In 2018, AxoGen developed a replacement for Dow&#x2019;s now-discontinued Triton X-200 and validated the Avance&#xAE; Nerve Graft processing using that replacement.</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">AxoGen also maintains as trade secret certain aspects of its process for preparing its Avance</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;"> Nerve Graft and continues to expand its trademarks across its product portfolio. In addition, the Company believes that its AxoGuard<a name="_Hlk534465710"></a></font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;"> line of products holds a competitive advantage in the marketplace that would be difficult, if not economically infeasible, for potential market entrants &#x2013; or current market participants &#x2013; to overcome. </font>
		</p>
		<p style="margin:0pt;punctuation-wrap:word-break;text-align:justify;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;punctuation-wrap:word-break;text-align:justify;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;text-decoration:underline;">Clinical Advances</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<a name="_Hlk534467067"></a><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;">Nearing completion of 170 subjects enrolled in RECON Study</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<a name="_Hlk534465803"></a><font style="display:inline;font-family:Calibri;font-size:11pt;">AxoGen&#x2019;s RECON study in support of its BLA submission is progressing well, with 168 subjects enrolled. The Company anticipates enrollment of the remaining two target subjects shortly. The study requires a one year follow up period for all subjects. The statistical analysis plan of the study is designed with an interim analysis to provide a safeguard for the assumptions used in the design of the protocol. It is possible to adjust the study sample size to maintain the original power of the study in the event the pooled variance of the standard deviation, a key statistical assumption in the power analysis of the study, is not consistent with the original assumptions.&nbsp;This interim analysis is designed to protect the validity and integrity of the study and is expected to be completed and reviewed by the FDA in the first quarter. </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Presented RANGER</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;"> registry data on more than 400 nerve repairs at 73rd Annual American Society of the Hand (ASSH) Meeting</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">The Company provided an update at the ASSH Meeting in October, which included the largest report to date on outcomes data for more than 400 nerve repairs with Avance</font><font style="display:inline;font-family:Calibri;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="display:inline;font-family:Calibri;font-size:11pt;"> Nerve Graft, and highlighted outcomes on sensory, mixed, motor, and long gap nerve repairs. The RANGER</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="display:inline;font-family:Calibri;font-size:11pt;"> data showed 85% meaningful recovery in a substantial and expanding outcomes population, and further demonstrated that Avance</font><font style="display:inline;font-family:Calibri;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="display:inline;font-family:Calibri;font-size:11pt;"> Nerve Graft outcomes consistently exceed those associated with synthetic conduits and are similar to nerve autografts without the associated donor site comorbidities.</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;">Previously Scheduled Investor Meetings to be Held This Week</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">Members of the AxoGen senior management team will again participate in this year&#x2019;s Trout Group Annual 1-on-1 Management Access Event in San Francisco, January 7 &#x2013; 9, 2019. These annual meetings provide an opportunity for management to meet individually with investors to address AxoGen&#x2019;s differentiated platform for nerve repair in an expanding set of applications.&nbsp; </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">The information discussed in these meetings is included on the corporate presentation which has been published to AxoGen&#x2019;s website. </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<a name="_Hlk510613690"></a><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;">About AxoGen<br /></font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">AxoGen, Inc. (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or discontinuity to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves.&nbsp;Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">AxoGen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;"> Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;"><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">peripheral nerves without the comorbidities associated with a second surgical site, AxoGuard</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;"> Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves, AxoGuard</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;"> Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">&nbsp;Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;"> Neurosensory &amp; Motor Testing System and AxoTouch<a name="_Hlk534185724"></a></font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;"> Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on peripheral nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;">Cautionary Statements Concerning Forward-Looking Statements<br /></font><font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">This Press Release contains &#x201C;forward-looking&#x201D; statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as &#x201C;expects,&#x201D; &#x201C;anticipates,&#x201D; &#x201C;intends,&#x201D; &#x201C;plans,&#x201D; &#x201C;believes,&#x201D; &#x201C;seeks,&#x201D; &#x201C;estimates,&#x201D; &#x201C;projects,&#x201D; &#x201C;forecasts,&#x201D; &#x201C;continue,&#x201D; &#x201C;may,&#x201D; &#x201C;should,&#x201D; &#x201C;will,&#x201D; and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our 2018 and 2019 guidance, our assessment on our internal control over financial reporting, our growth, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events, or otherwise.</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;font-weight:bold;">Contacts:</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">AxoGen, Inc.<br />Kaila Krum, VP, Investor Relations and Corporate Development<br />kkrum@AxoGenInc.com</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-family:Calibri;">The Trout Group &#x2013; Investor Relations<br />Brian Korb <br />646.378.2923<br />bkorb@troutgroup.com</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex-99d1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d1g001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "5 =0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MBB@ HHHH **** "BL7Q]\1=#^%OAF?6/$6J6>D:;;CYY[A]JY[*!U9CV4 D]
MA7PO^TK_ ,%;M2UM[C2OAO:G2[3E#K%Y&&N9/>*(Y5!Z%LG!Z*:][).&\?FL
M^7"P]WK)Z17S_17?D?*\3<9Y5D5/GQ]3WGM!:R?HNB\W9>9]K_%7XX^$O@EH
M_P!N\4Z]I^CPL"8UFDS--CKLC&7<^R@U\F_&#_@L=I]@\MKX&\,RW[+D+?:L
M_E1'W$*'<P^KJ?:OE/X8? _XC?MB>-9[BPAU+7+F60"\U?4)F,$!_P"FDS9Y
M _A7+8Z"OMW]G[_@E'X+^'4<-]XOE;QAJRX8PN#%81'T$8.Z3'JYP?[HK[FI
MD/#V1+_A4J.M5_DCHON3T_[>:OV/R^AQ5Q?Q1*V1TEAJ'_/R6K?HVG?TC%V?
MVCYC3]JO]H;]J#4I+7P]>:])&S8:+0+3[-%!G^],HW*/=Y*ZK0?^"9OQJ^*.
MVX\5>(;731)RZZEJLM[<?DF]3_WW7Z):+HVG^&-,AL=/M;/3[.W&V*"WB6*.
M,>@50 /PJX#FO*K<?5*7N97AJ=&/^%.7WZ+\'ZGO8;PGI5_WF>8RKB)]4Y-1
M^Z[?XKT/A30O^"-%]IY65OB6;2X'.;71V^4_[WG@_I7;^'?V+_C;\'-LGA#X
MSG4UC^[9:S;RFV8?W<,TP7/JH!]Z^M**\FOQMFU?3$SC-=I0@U_Z3^I[^&\-
M,@POO8.G.E+^:-6HG_Z7;\#QCX=_M$^)O#>IV^B?%?PROA>_N'6&VUJRD^T:
M+?R$X5?,R3;NQX"R'YCT.2!7L^<U#J.FV^L6$UK=V\-U:W"&.6&5 \<BD8(8
M'@@CL:AT+18O#VEQV=NTIM[<;8ED<N8U[+D\D#H,Y.*^?Q=:C6?M*<.1]4K\
MOJKW:]+M=K;'U>7X;$8=>RJU'4CT<K<WI*R2EY.R?>[U+E%%%<9Z04444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A/[
M7'[>7AG]F"SDT^/9KGBR1,Q:9%)\MOD</.P^XO<+]YN. #N'E'[<O_!2N'P,
M]YX1^'MS#=:RN8;[6$P\5B>A2'LT@[MRJ].3G;\*>$O"/B'XU>/(=-TNWOM<
MU[6)BV-QDDE<G+.[L>!U+,QP.237ZAPKP#[>"Q^;>Y2W47HVN\G]F/XOR6_X
M=QWXK?5JCRK(?WE=OE<DKJ+VM%?:E^">FKNEM?&CX^>,/VE?&2W_ (BO[C4+
MB1]EI90J1!;;C@)%$.F>!GEFXR2:]_\ @7_P3^T;P'X:A\;?''5K?PSH:XD@
MT>6;RKBY[@2D?,"1_P LX\N>Y4@BL+2?'?@?]A2W:/0TTWQ]\50I2?5&_>:5
MH#D8*0]#+(.A88^HY0^"_$[XM>)/C+XFDUCQ-J]YJ]])G#S/\L0Z[44?*B_[
M*@"OTKV6*QE-8;+_ /9\.M.9*TI+^XOLK^\]7NEU?XS[? Y=6>,S?_:\6W?D
M<KPB_P#IY+[<E_)'W5M*5]%]B?$C_@J[HGP]T=/#_P )_"-I!I]DOE075[%Y
M%N@]8[>,@D'KEF4YZK7S?\1?VW?BI\3YI#J/C/6+>%_^7?3Y/L4('IB+;N'^
M]DUY3179EW"N5X+6G24I=92]Z3?>[V^5CS<XX\SS,O=K5W&&RA#W(I=K1M=+
MSN6K_7;[5)S+=7EU<2,<EY96=C^)-;_@?XW^,?AK=I-H/B?7-*:,YVV]XZQM
M[,F=K#V((KEJ*]RIAZ52'LYQ379I-?<?,4<57I5/:TIN,NZ;3^]:GWS^QY_P
M5.D\2ZS:>&_B5]EAFNF$5MKD2"*-G/ %P@^5<G^-<*.,@#+5]O@[AD5^$]?J
M%_P2^_:%N/C+\"7T?4[AKC6?!\B6;R.VYYK9@3 Q/J K)_VS!ZFOQ?Q X/H8
M2G_:6!CRQO:45LK[-=E?1K;56/Z3\)?$3%8^M_8V:3YYV;A)[NV\7W=M4][)
MW;T/I:BBBOR4_?0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ****  G KX)_X*"_\%$VU&6^\"_#^^*VJ[H-5UB!^9CT:&!A
M_#U#..O0<<G0_P""DG[>C6+7WPZ\%WNV;F'6]1A;E.S6T;#OV=AT^[UW8^%]
M&TB;7-02WAVAFR6=SM2)1R68]E Y)K]CX&X)CRQS3,EIO"+_ /2I?HOF^A_.
MOBAXES<Y9)DTM=JDUWZPB_PD_DNI>\"^!K_XA:^NGV"Q*VPS3SSN([>SA7EY
M97/"(HZD^P&20#W?B/XRV/PW\*77A/X>R30VMXGE:QX@*&*]UOUC3O#;>B#Y
MF'+GG:.2\0^,8K/06\/Z(SQZ27#W<Y7;+JLJ]'?N(U_@CZ#J<L2:YFOU66&^
ML24Z_P *U4?/HY=WV6RW>MK?@\,9]3@Z>%?OM6E-;I/>,7T3VE+=[*T;\Q11
M17H'DA1110 4444 %?5W_!(+Q;)HW[2.I:7N_P!'UG1I05]9(Y(W4_@OF#_@
M5?*-?1W_  2K@:7]K_3&7[L6GW;-]/+Q_,BOG>+:<9Y-B5+^1O[M5^*/K^ :
MTZ?$>"E#?VD5\F[/\&S]2J***_ED_ND**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "OEO_@HY^VK_ ,*'\+GPGX;N@/%VLPYD
MFC/S:5;MQO\ :1N0H[#+?W<^N_M3_M%:;^S+\([[Q%>;)KQO]'TVT)P;NY8'
M:O\ NC!9CV53WP#^0GCGQOJGQ(\7ZAKNLW4E[JFJ3-/<3/U9CZ>@ P !P  !
MP*_2. .%%CZWU[%+]U!Z)_:E_DNO=Z=S\:\6./'E6&_LS R_?U%JUO"+Z^4I
M;+LKO1V,N21II&9F9F8Y))R2:L'4#!I[6\/RK-@S-WEQR%_W1UQW/)Z#%6BO
MW_E3/Y.4FM@HHH'-,D**]E^'O[%NOZSX73Q-XPO['X>>$3@C4=9RLUP.N(+<
M?O)&(Y X##H32ZI\4?AC\*,V_@CPD?%FH1\'7/%8\R(GN8K)2(]O<&4L?45Y
M+SBE.;I81.K);\OPKUD[1OW2;EY'O1X?K4Z:KXZ2HQ>JYK\TEWC!)RL^C:47
M_,>5^&_!FL>,;GR='TG4M5F'5+.U>=OR4$UU;?LL?$Q+;SC\/O&GE@9)_L:X
MS^6S-0>,/VC/''CF'R+[Q)J2V(X6QM)/L=G&/18(ML8_!:Y73/$.H:)?K=6=
M]>6=TIW+-#,T<@/J&!S6W^W25_<B^VLOQ]W\CG_X3(2M^\FN_NP_\EM/_P!*
M&ZUH5]X;U&2SU&SNK"[B^_!<PM%(GU5@"*JU]N?L@>(XOV^OAMXB^'OQ$"ZM
MK6B6@NM'UV1 U_;*3L.9.K;7*'D_.&(;. :^,_%OAFZ\%>*M3T:^7R[W2;N6
MSN%'\,D;E&'Y@URY9FSQ%>K@Z\>6K3M=)W335U).RT?5-73T._.N'UA,+0S'
M#3YZ%:_*VK24HNTHR5VKKHT[-:HSZ^O?^".7A-M2^.GB/667=%I6C& '^[)-
M,F/_ !V)Z^0J_2;_ ()"?#5O#'P"U3Q%-'MF\3ZB?*;'WX( 8U_\B&:O%\0,
M8L/DE5=9VBOF]?P3/H_"?+7B^):#MI3YIOY*R_\ )FCZRHHHK^:S^T HHHH
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M*6EF/]I\<MZ*N6/IC)'U/\&O^"5.B_#[26\2?%OQ!9BSL4\^>QMIS#:Q*/\
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M/$.M74/EZIXR<7[DCYEMP"(%^A4LX_ZZU^\\4<01R?!?6$DY-I16U^_R2O\
M@?RKP+PG/B+,_JDI.,$G*4EJTMEOU;:^5WT/SZ_X9A^)7_1//'/_ ((;K_XW
M1_PS#\2O^B>>.?\ P0W7_P ;K]EZ*_-O^(K8O_GQ'[V?L_\ Q ? ?]!4_P#P
M&)^(OC#P%KOP\U&.S\0:+JVAW<T8F2#4+.2UD="2 P5P"5R",],@UDU]A?\
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M2*>#D H _.S]MCX(R>#?VUM4TCRVBL_%6I17]HV,!TNI/FQ])3(O_ :^I/\
M@KMX3D3]GKPSJ%E&4CT'6(T(0<0HT+JI]@&5!_P(5WO[>'[,\_QG\+Z3XDT*
MW$WBSP7<K?6D0X:_B5E=X,_WCM#+GN".-Q->G_$OP!H_[0WP=O\ 0[_<^E^(
MK(;9 N'B) >.0 ]&5@K#/<<U^E5>*XS_ +-Q<]?8WC-=?LJ_SCJO.ZZ'XO0X
M#G3_ +:R^FK+$*,J;Z?;DE?^[/1]DT^J#X#_ !7L_C=\(M!\3V,D<D>J6B/*
MJG_4S 8DC/NKAA^%==7YD>&/'7Q2_P""8'Q$NM*OM/\ [2\,7TV\1R[OL.H@
M<"6&09\N7: ".3TW*<*:^D_ _P#P5O\ ACXBM$_M>'7O#UQCYUEM?M$8/^RT
M9)(]RH^E>7FW!>,A-U\MC[:A+6+CJ[/HTM;K;;\=#W.'_$G+ZE)83.9_5\3#
M2<9^ZKK=IO2SWWOZK5_3NIZ7:ZU826MY;P7=K,NV2&:,21R#T*G@_C7FFL_L
M2_";7KIIKCP#X=61CD^1;_9U/X1E1^E<7J'_  5'^#=E!OC\0:A>-C.R+2K@
M,?\ OM%'ZUQ6J?\ !5NW\87QT[X=_#WQ1XJU)N%$J>6!_M;(O,8CZ[?J*Y,#
MP_G].[H4ZE-=6VX+YMN*/0S3BSA.K98JM2K/HDE5?HE%29[QX7_9+^&7@R=9
MM/\  OAF&:/E97L4FD3Z,X)'X5R_QP_;>\&?!*[70=,63Q5XL<^1;:%HJ^=+
MYG0(Y4$1_3EO137B7Q!L/C#\2O#S:M\7/'6F_"'P;*<'3--;_3;L'_EFJHQ=
MV8<;2['_ *9]JM_!_P#9=U7Q-8&Q\"Z)>?"SP?=+LN_$6IH)/%.NQ]Q&#_QZ
MQM_P'L0#R*].GE.'7^T9IB/:V[2;CZ.;NY/^[34GW:6IXE7/\6_]DR+!^P<N
M\(J;7=4E907:=9Q7:,GH>7?%_P 5_$#]I;XAP:'K4:^(/$I??9^#-*E_XEFA
M#IYNH2J<-(N>4W<$_,R?ZMOJ+]DG]AS3/@&__"0Z]-#X@\<W28EO2@$&G@C'
ME6RX 50/EW8!P, *ORUZ5\%/@'X6_9^\+_V5X8TV.SC?#7%PWSW%XX_CED/+
M'K[#/  XKLJX<XXIE6H_4<"O9T=M%9R^2V7E=M_:E)GI\.\"PP^(_M/-)>UQ
M&ZN^91?>[2YI+^:R4=H1BMRBBBOCS]$"BBB@ HHHH X?]H_XKO\ !7X,:YX@
MM[:6]U"V@,=C;QQF1IKA_EC&!S@,<G_94U^0VI^#_$^M:E<7EWI.N7%U=RM-
M-*]G(6D=B2S$XZDDFOVQHK[3A?BY9+3G&%!3E-ZOFMHMEL_-_,_-^./#Z7$E
M:G.IB73A332BHWU;U=^9;Z+;2WF?CS^SW^SAKGQA^,WA_P /7&EZI:V5]=+]
MLGDMGC6*W7YY3N( !V*0/4D"OV T^PATJPAM;>-(;>VC6**-!A451@ #T %3
M45R\4<4U<ZJ0E.')&"=E>^KW>R\E\CNX&X%P_#=&K"G4]I*HTW)JVB6BM=[-
MM[]?(****^5/NCX5_P""P_A'4-:\3>!;BQL+R\_T6\C<P0M)MP\)&=H./O&O
MC'_A7OB#_H!ZQ_X!2?X5^W%%?H^1^(E3+L#3P2H*7)?7FM>[;VL^Y^-\4>$-
M+.,SJYD\4X>TM[O(G:T4M^9;VOL?B/\ \*]\0?\ 0#UC_P  I/\ "OI3_@G7
M^Q/<_%+QW_PE'BS3;BW\.^'Y@8;:ZA*?VC<C!"E6',:<,W8G"\C=C])**VS3
MQ,Q6*PL\/1I*FY*W,I7:76VBU\^GJ<^1^">"P.-IXO$UW5C!WY7%)-K:_O.Z
M3UMUZZ !@5\,_P#!7SX,7FK:SX3\6:98W-Y))%)I5V((3(R[3YD1(4?[4O/L
M*^YJ*^*R'.*F5XV&,IKFY;W5[735K?J?I7%7#M+/,MJ9=5ER\UFI6O9IIWMI
MZ;[,_$?_ (5[X@_Z >L?^ 4G^%?07_!-+Q!K?PG_ &FK&"\TO5+?2_$L#Z9<
M/):R+'&YP\3'(Q]] N>P<U^FU%?;YEXD/&X2IA*F&5IIKXMNS^'H]3\QR7P9
M66X^ECZ.,?-3DI6Y%K;=?%LU=/U/S_\ V[O^"=&LV7BW4/&/@'3Y-4TW49&N
M;[2K==UQ:2GEVB3JZ,<G:OS*3P".GQK?V%QI5Y);W4,UO<0MMDBE0HZ'T(/(
M-?N561XE^'^@^,PO]L:)I.J[1@?;+..? _X$#2R/Q*Q&$HQP^+I^T4=$[V=O
M/1I^NGG<KB?P7PF/Q,L7E]7V+D[N+CS1N][:IQ]-5VLM#\1J[SX/?LR^./CM
M?QP^&_#U_=V[L U[)&8K2(>K2MA>/0$D]@:_6K3/@9X)T6X$UGX/\+VDRG(>
M'2H(V!^H6NI1%C4*JA548  Z5Z6,\5I.%L+0L^\G=?<DK_>>-EW@/%5%+'XJ
M\>T(V;_[>;=O_ 6>!?L9_L'Z/^R_9_VI?31:UXON8]DMX$Q%9J>L< /.#T+G
MEO11Q7OU%%?EF89CB,=7>)Q4N:3Z_HNR\C]URC)\)EF%C@\#!0A'HOQ;>[;Z
MME?5M*M=>TNYL;ZWAO+.\B:"X@F0/'-&P*LC*>"I!((/!!K\5_\ @I)_P0D\
M7?"'Q1J/BSX.Z9=^+/!=T[7#Z+;9EU/1L\E$3[UQ$/X2N9 ."#@N?VPHKCN>
MD?R@:QHUYX>U.:RU"TN;&\MV*2P7$312Q,.S*P!!]C5:OZIO&_PB\)_$Q57Q
M)X7\/>(%484:EIT-U@>@\Q36+X=_97^&'A"^6ZTGX<> ]+N5.Y9;30+2&13Z
MAEC!I\Q/*?SR_LK?\$Y/B]^V'JUO'X1\(Z@ND3,!)K>HQM::9 O=O.8?/C^[
M&';_ &:_6[X4?\$G/"/[$W["_P 6+.S'_"3^/_$W@O5;*_UIX,.V^SEQ;VR<
MF.+=M.,EG8 L>%5?NA5"* !@#@ =J*.8=C^8/X)?LQ>+/B7\9O"/AV;PSXA@
MAU[6;/3I)9-.F1(DEG2-F9BN  &))/0"OZ>H($M8$CC54CC4*J@8"@< "G44
MFP2L?G3_ ,%DO^"/]]^U5JK?$[X9PVY\=0P+%JVE.ZPKKL<:[4DC=L*+A5 7
M#$!U51D%1N_&GX@_#3Q%\)O$T^B^*-#U;P]JUL<26FHVCVTR_P# 7 ./?H:_
MJLK*\6^!-#\?:?\ 9-=T;2M:M<Y\F_M([F/_ +Y<$4^87*?RF5W'P1_9H^('
M[2&OIIG@7PCKWB:Z9PC&RM6:&$GO)*<1QCW=@/>OZ2K+]C[X2Z;=_:+?X6_#
MJWN <B6/PW9JX/U$>:[[3-+M=%L8[6SM[>TMH1MCBAC$<:#T"C@4<P<I^=W_
M  2__P""&=C^S?KNG^/_ (K26.O>,[-EGTW2(#YMCHT@Y$KL1B:=>V!L0C(W
MG:R_8?[<_C>[^'7[&_Q.U?3X;B?4K?PW>QV201EY&N)(FBBPJ\G]XZ]*]6HJ
M;E'\KG_"F?&'_0I^)?\ P63_ /Q-=+\&/V8_%OQ*^,'A3P[+X9\16\.O:Q::
M<\KZ=,BQ+-,D98L5P  V23TQ7]/U%5S$\I';6\=G;1PQJL<<2A$51@* , "O
MS1_X.3M6UK7_ (7?#/PAH^EZIJBWNJW6L72V=K),(C!$L4>[:#C/VF3&?[IK
M],J*DH_E<_X4SXP_Z%/Q+_X+)_\ XFOO_P#X-V/V?-:@_;"\1>*-:T35-.M_
M#OAN6.W>[M'A!N+B:)!M+ 9_=K-T]:_:2BJYB>4X']JOX9ZA\:/V9/B%X1TF
M98-4\3>';_3+1V;:HEFMW1 Q[*68 GT)KXD^*-I<?M.V/C_Q/HFJ_P#"/PV/
MP_T'1]5\'WFH6%BE]?6-YJ$M[HVH)/MGMU6.1$61)($83A@[KT_1FN5\8? K
MP3\0M>@U77_!WA77-4M0!#>:AI,%S/%CIM=T+#'L:11\$?';]BKQ)_P4?^,&
MO?$SP3K7_"/>$KB6+3=+GF+PC78X((U:]C 'S1-(7C1^CK"&&5922OT?CC6*
M-55555&  , "BCF =0!BBBD!3US0+'Q/IDECJ5C::A9S#$D%S"LT4@]U8$'\
M:\IUS]@'X.^(;IIKCP+I<;,<D6TDUJO_ 'S&ZC]***[,+F&*PW^[U)0_PR:_
M)GGX[*<#C+?7*,*EOYHJ7YIDWA_]@_X0^&9UDMO >BR,O(^U![M?RE9A720Z
M>UGJ-QX;\+QZ9X5MK5%=Y+6P1CAN/W:#:B,/5E<?[-%%;2Q^)Q%Y8BI*=E=<
MS<NJ[W.195@L)RPPE*--2=GR14=+-[Q2:VZ$GA;X!^'?#OB)=<N(;C7O$0&/
M[6U:7[5=)[1Y&R$?[,2HOM7:445QUJ]2J^:HV_7HNR[+R/3P^%HT(\E&*BMW
M9;ON^[?5O5A1116)T!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
